Capstone Therapeutics (CAPS) Expected to Announce Quarterly Earnings on Friday

Capstone Therapeutics (NASDAQ:CAPS) is expected to be issuing its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Capstone Therapeutics to post earnings of $5.70 per share and revenue of $24.60 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 18, 2026 at 9:30 AM ET.

Capstone Therapeutics Stock Performance

CAPS stock opened at $2.14 on Wednesday. The company has a quick ratio of 0.39, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. Capstone Therapeutics has a 1 year low of $1.92 and a 1 year high of $34.80. The stock’s 50 day moving average price is $4.31 and its 200 day moving average price is $10.83.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Capstone Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 23rd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Capstone Therapeutics has a consensus rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury.

The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.